Mp65-15 Humanized Anti-Cd47 Antibody (Hu-5f9-G4) for Metastatic Bladder Cancer Is Superior to Conventional Chemotherapy With Cisplatin and Gemcitabine in a Murine Bladder Cancer Model.

Journal of Urology - Netherlands
doi 10.1016/j.juro.2018.02.2081
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin‐Based Chemotherapy for Muscle‐Invasive Bladder Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

1,25D3 Enhances Antitumor Activity of Gemcitabine and Cisplatin in Human Bladder Cancer Models

Cancer
Cancer ResearchOncology
2010English

Complete Response to Anti-Pd-L1 Antibody in a Metastatic Bladder Cancer Associated With Novel MSH4 Mutation and Microsatellite Instability

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

CD47-targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Role of Combination Chemotherapy With 5-Fluorouracil, Cisplatin and Paclitaxel for Advanced Gall Bladder Cancer

Journal of Cancer Therapy
2014English

Intra-Arterial Chemotherapy for Bladder Preservation in Patients With Locally Advanced Bladder Cancer

Japanese Journal of Urology
Urology
2009English

Antibody-Drug Conjugates in Bladder Cancer

Bladder Cancer
OncologyUrology
2018English

Immune Checkpoint Inhibitors for Metastatic Bladder Cancer

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2018English

Docetaxel as Second Line After Failure of Gemcitabine/Cisplatin Regimen in Advanced and/or Metastatic Urinary Bladder Cancer Patients in Egypt

Research in Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy